Document And Entity Information
Document And Entity Information - shares | 3 Months Ended | |
Mar. 31, 2022 | May 11, 2022 | |
Document Information [Line Items] | ||
Entity Central Index Key | 0001742927 | |
Entity Registrant Name | REVIVA PHARMACEUTICALS HOLDINGS, INC. | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Period Focus | Q1 | |
Document Fiscal Year Focus | 2022 | |
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Mar. 31, 2022 | |
Document Transition Report | false | |
Entity File Number | 001-38634 | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 85-4306526 | |
Entity Address, Address Line One | 19925 Stevens Creek Blvd., Suite 100 | |
Entity Address, City or Town | Cupertino | |
Entity Address, State or Province | CA | |
Entity Address, Postal Zip Code | 95014 | |
City Area Code | 408 | |
Local Phone Number | 501-8881 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | true | |
Entity Ex Transition Period | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 15,133,286 | |
Warrant [Member] | ||
Document Information [Line Items] | ||
Title of 12(b) Security | Warrants to purchase one share of Common Stock | |
Trading Symbol | RVPHW | |
Security Exchange Name | NASDAQ | |
Common Stock [Member] | ||
Document Information [Line Items] | ||
Title of 12(b) Security | Common Stock, par value $0.0001 per share | |
Trading Symbol | RVPH | |
Security Exchange Name | NASDAQ |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) | Mar. 31, 2022 | Dec. 31, 2021 |
Assets | ||
Cash | $ 23,421,237 | $ 29,687,944 |
Prepaid expenses and other current assets | 1,847,165 | 1,716,057 |
Total Assets | 25,268,402 | 31,404,001 |
Liabilities | ||
Accounts payable | 1,425,834 | 509,583 |
Accrued expenses and other current liabilities | 2,197,640 | 1,835,228 |
Total current liabilities | 3,623,474 | 2,344,811 |
Warrant liabilities | 283,720 | 372,730 |
Total Liabilities | 3,907,194 | 2,717,541 |
Commitments and contingencies (Note 8) | ||
Stockholders' equity | ||
Common stock, par value of $0.0001; 115,000,000 shares authorized; 15,133,286 and 14,433,286 shares issued and outstanding as of March 31, 2022, and December 31, 2021, respectively | 1,513 | 1,443 |
Additional paid-in capital | 95,556,672 | 95,516,986 |
Accumulated deficit | (74,196,977) | (66,831,969) |
Total stockholders' equity | 21,361,208 | 28,686,460 |
Total Liabilities and Stockholders' Equity | $ 25,268,402 | $ 31,404,001 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares | Mar. 31, 2022 | Dec. 31, 2021 |
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized (in shares) | 115,000,000 | 115,000,000 |
Common stock, shares issued (in shares) | 15,133,286 | 14,433,286 |
Common stock, shares outstanding (in shares) | 15,133,286 | 14,433,286 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Operating expenses | ||
Research and development | $ 5,830,018 | $ 391,161 |
General and administrative | 1,620,139 | 1,480,967 |
Total operating expenses | 7,450,157 | 1,872,128 |
Loss from operations | (7,450,157) | (1,872,128) |
Other income (expense) | ||
Gain on remeasurement of warrant liabilities | 89,010 | 923,480 |
Interest and other income (expense), net | (232) | 148 |
Total other income (expense), net | 88,778 | 923,628 |
Loss before provision for income taxes | (7,361,379) | (948,500) |
Provision for income taxes | 3,629 | 800 |
Net loss | $ (7,365,008) | $ (949,300) |
Net loss per share: | ||
Basic and diluted (in dollars per share) | $ (0.40) | $ (0.10) |
Weighted average shares outstanding | ||
Basic and diluted (in shares) | 18,466,586 | 9,231,737 |
Condensed Consolidated Statem_2
Condensed Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited) - USD ($) | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
Balance (in shares) at Dec. 31, 2020 | 9,231,737 | |||
Balance at Dec. 31, 2020 | $ 923 | $ 63,774,920 | $ (58,310,093) | $ 5,465,750 |
Net loss | $ 0 | 0 | (949,300) | (949,300) |
Balance (in shares) at Mar. 31, 2021 | 9,231,737 | |||
Balance at Mar. 31, 2021 | $ 923 | 63,774,920 | (59,259,393) | 4,516,450 |
Balance (in shares) at Dec. 31, 2021 | 14,433,286 | |||
Balance at Dec. 31, 2021 | $ 1,443 | 95,516,986 | (66,831,969) | 28,686,460 |
Common stock issued in connection with warrant exercises (in shares) | 700,000 | |||
Common stock issued in connection with warrant exercises | $ 70 | 0 | 0 | 70 |
Stock-based compensation expense | 0 | 39,686 | 0 | 39,686 |
Net loss | $ 0 | (7,365,008) | (7,365,008) | |
Balance (in shares) at Mar. 31, 2022 | 15,133,286 | |||
Balance at Mar. 31, 2022 | $ 1,513 | $ 95,556,672 | $ (74,196,977) | $ 21,361,208 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Cash flows from operating activities | ||
Net loss | $ (7,365,008) | $ (949,300) |
Adjustments to reconcile net loss to net cash used in operating activities | ||
Change in fair value of warrant liabilities | (89,010) | (923,480) |
Stock-based compensation expense | 39,686 | 0 |
Changes in operating assets and liabilities: | ||
Prepaid expenses and other current assets | 110,213 | (1,012,064) |
Accounts payable | 674,930 | (536,743) |
Accrued expenses and other current liabilities | 362,412 | 305,344 |
Net cash used in operating activities | (6,266,777) | (3,116,243) |
Cash flows from financing activities | ||
Proceeds from exercise of warrants | 70 | 0 |
Net cash provided by financing activities | 70 | 0 |
Net increase (decrease) in cash | (6,266,707) | (3,116,243) |
Cash, beginning of period | 29,687,944 | 8,760,462 |
Cash, end of period | 23,421,237 | 5,644,219 |
Supplemental disclosures of cash flow information: | ||
Cash paid for taxes | 675 | 1,600 |
Cash paid for interest | $ 0 | $ 0 |
Note 1 - Organization and Natur
Note 1 - Organization and Nature of Operations | 3 Months Ended |
Mar. 31, 2022 | |
Notes to Financial Statements | |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | 1. ORGANIZATION AND NATURE OF OPERATIONS On December 14, 2020, July 20, 2020 Reviva Pharmaceuticals, Inc. was originally incorporated in the state of Delaware and commenced operations on May 1, 2006 2014. |
Note 2 - Summary of Significant
Note 2 - Summary of Significant Accounting Policies and Basis of Presentation | 3 Months Ended |
Mar. 31, 2022 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10 8 X. three March 31, 2022, not may December 31, 2022. The condensed consolidated balance sheet as of December 31, 2021, not 10 December 31, 2021, 10 March 15, 2022. Use of estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting periods covered by the financial statements and accompanying notes. Significant areas requiring the use of management estimates include, but are not Concentration of credit risk and other risks and uncertainties Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. Substantially, all the Company’s cash is held in demand deposit form by one not The Company is subject to all of the risks inherent in an early-stage company developing new pharmaceutical products. These risks include, but are not may |
Note 3 - Public Offering
Note 3 - Public Offering | 3 Months Ended |
Mar. 31, 2022 | |
IPO [Member] | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | 3. PUBLIC OFFERING On June 1, 2021, one one one one one one one no not one one one one |
Note 4 - At the Market Offering
Note 4 - At the Market Offering | 3 Months Ended |
Mar. 31, 2022 | |
Notes to Financial Statements | |
At the Market Offering [Text BLock] | 4. AT THE MARKET OFFERING In January 2022, may March 31, 2022, not |
Note 5 - Loss Per Share
Note 5 - Loss Per Share | 3 Months Ended |
Mar. 31, 2022 | |
Notes to Financial Statements | |
Earnings Per Share [Text Block] | 5. LOSS PER SHARE Basic and diluted net loss per share is computed by dividing the net loss for the period by the weighted average number of common stock outstanding during the period. For the three March 31, 2022 2021, not |
Note 6 - Warrants
Note 6 - Warrants | 3 Months Ended |
Mar. 31, 2022 | |
Notes to Financial Statements | |
Warrants [Text Block] | 6. WARRANTS As of March 31, 2022, Each public warrant entitles the holder thereof to purchase one of $11.50 No We may not of $0.01 ● if, and only if, the reported last sale price of the common stock equals or exceeds $21.00 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations), for any 20 trading days within a 30 trading day period ending on the third ● if, and only if, there is a current registration statement in effect with respect to the issuance of the shares of Common Stock underlying such Public Warrants at the time of redemption and for the entire 30 ● at any time while the public warrants are exercisable ● upon not 30 The private warrants are substantially similar to the public warrants except such private warrants; ● are exercisable for cash or on a cashless basis, at the holder’s option ● cannot be redeemed by us, so long as they are still held by the initial purchasers or their affiliates. ● The redemption price is to be calculated as the 10 one In no The Company classified the private warrants pursuant to ASC 815 March 31, 2022 three March 31, 2022, The exercise price and number of shares of common stock issuable on exercise of the warrants may Further, there were assumed warrants outstanding to purchase an aggregate of 126,268 shares of common stock. These warrants were classified as equity as of March 31, 2022, December 31, 2021. In connection with the Offering, the Company issued Pre-Funded Warrants exercisable for 5,066,600 shares of common stock. Total proceeds from the sale of Units including the Pre-Funded Warrants were approximately $19.0 million and the Pre-Funded Warrants are exercisable into one share of common stock at an exercise price of $0.0001 per share at any time after issuance. Additionally, in connection with the Offering, the Company issued Investor Warrants exercisable for 6,900,000 shares of common stock with an exercise price of $4.125 per share of common stock any time after issuance. The Investor Warrants expire on June 1, 2026. three March 31, 2022. no |
Note 7 - Stock Option Plan and
Note 7 - Stock Option Plan and Stock-based Compensation | 3 Months Ended |
Mar. 31, 2022 | |
Notes to Financial Statements | |
Share-Based Payment Arrangement [Text Block] | 7. STOCK OPTION PLANS AND STOCK-BASED COMPENSATION Stock-Based Compensation Expense The Company records stock-based compensation expense in connection with the amortization of the fair value of stock options granted to employees, non-employee consultants and non-employee directors. During the three March 31, 2022 2021, March 31, 2022 2021, Determining Fair Value Valuation and Recognition – The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes pricing model utilizes the following assumptions: Expected Term – Expected life of an option award is the average length of time over which the Company expects employees will exercise their options, which is based on historical experience with similar grants. Expected Volatility - Expected volatility is based on the Company’s historical stock volatility data over the expected term of the awards. Risk-Free Interest Rate - The Company bases the risk-free interest rate on the implied yield currently available on U.S. Treasury zero Dividend Yield – The Company has not not There were no options granted during the first 2022. Activity under the stock plans for the three March 31, 2022, Shares available for Grant Number of Options Outstanding Weighted Average Exercise price per share Balance, December 31, 2021 1,257,334 192,898 $ 8.46 Balance, March 31, 2022 1,257,334 192,898 $ 8.46 Vested and expected to vest, March 31, 2022 192,898 $ 8.46 Options outstanding under the stock plans are as follows as of March 31, 2022: Options Outstanding Weighted average remaining contractual life (years) Options Exercisable Weighted Average Exercise Prices 48,724 0.60 48,724 $ 11.89 16,747 2.68 16,747 $ 31.33 81,227 9.07 20,957 $ 4.38 46,200 9.65 15,625 $ 3.72 192,898 6.51 102,053 $ 8.46 |
Note 8 - Commitments and Contin
Note 8 - Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2022 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | 8. COMMITMENTS AND CONTINGENCIES Clinical trials Since 2010, 2 may third not may 30 Indemnification From time to time, in its normal course of business, the Company may may third may not no may Operating Leases The Company adopted ASC 842 January 1, 2020. one twelve 19925 100, 95014. February 2021 February 1, 2022, |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2022 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10 8 X. three March 31, 2022, not may December 31, 2022. The condensed consolidated balance sheet as of December 31, 2021, not 10 December 31, 2021, 10 March 15, 2022. |
Use of Estimates, Policy [Policy Text Block] | Use of estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting periods covered by the financial statements and accompanying notes. Significant areas requiring the use of management estimates include, but are not |
Concentration Risk, Credit Risk, Policy [Policy Text Block] | Concentration of credit risk and other risks and uncertainties Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. Substantially, all the Company’s cash is held in demand deposit form by one not The Company is subject to all of the risks inherent in an early-stage company developing new pharmaceutical products. These risks include, but are not may |
Note 7 - Stock Option Plan an_2
Note 7 - Stock Option Plan and Stock-based Compensation (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Notes Tables | |
Share-Based Payment Arrangement, Option, Activity [Table Text Block] | Shares available for Grant Number of Options Outstanding Weighted Average Exercise price per share Balance, December 31, 2021 1,257,334 192,898 $ 8.46 Balance, March 31, 2022 1,257,334 192,898 $ 8.46 Vested and expected to vest, March 31, 2022 192,898 $ 8.46 |
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block] | Options Outstanding Weighted average remaining contractual life (years) Options Exercisable Weighted Average Exercise Prices 48,724 0.60 48,724 $ 11.89 16,747 2.68 16,747 $ 31.33 81,227 9.07 20,957 $ 4.38 46,200 9.65 15,625 $ 3.72 192,898 6.51 102,053 $ 8.46 |
Note 3 - Public Offering (Detai
Note 3 - Public Offering (Details Textual) $ / shares in Units, $ in Millions | Jun. 01, 2021USD ($)$ / sharesshares |
Public Offering [Member] | |
Number of Units, One, Issued (in shares) | 4,133,400 |
Number of Units, Two, Issued (in shares) | 5,066,600 |
Shares Issued, Price Per Share, One (in dollars per share) | $ / shares | $ 3.75 |
Shares Issued, Price Per Share, Two (in dollars per share) | $ / shares | $ 3.7499 |
Proceeds from Issuance or Sale of Equity, Net | $ | $ 31.5 |
Payments of Stock Issuance Costs | $ | $ 3 |
Public Offering [Member] | Common Stock [Member] | |
Stock Issued During Period, Shares, New Issues (in shares) | 4,133,400 |
Over-Allotment Option [Member] | |
Number of Units, One, Issued (in shares) | 1,200,000 |
Pre-Funded Warrant [Member] | |
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.0001 |
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 |
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 5,066,600 |
Investor Warrant [Member] | |
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 4.125 |
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 0.75 |
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 6,900,000 |
Note 4 - At the Market Offeri_2
Note 4 - At the Market Offering (Details Textual) - H.C. Wainwright & Co [Member] - The Market Offering Agreement "ATM Agreement" [Member] - USD ($) shares in Thousands, $ in Millions | 1 Months Ended | |
Jan. 31, 2022 | Mar. 31, 2022 | |
Sale of Stock Agreement, Maximum Aggregate Gross Proceeds | $ 12.9 | |
Shares, Issued (in shares) | 0 |
Note 5 - Loss Per Share (Detail
Note 5 - Loss Per Share (Details Textual) - shares | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Warrant [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | 13,883,732 | 7,007,581 |
Share-Based Payment Arrangement, Option [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | 192,898 | 65,471 |
Earn-out Shares [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | 1,000,000 |
Note 6 - Warrants (Details Text
Note 6 - Warrants (Details Textual) | Jun. 01, 2021USD ($)$ / sharesshares | Mar. 31, 2022USD ($)$ / sharesshares | Mar. 31, 2021USD ($) | Dec. 31, 2021USD ($) |
Gain (Loss) on Derivative Instruments, Net, Pretax, Total | $ | $ 89,010 | $ 923,480 | ||
Public Warrants [Member] | ||||
Class of Warrant or Right, Outstanding (in shares) | 6,325,000 | |||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | |||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 11.50 | |||
Class of Warrant or Right, Redemption Price Per Share (in dollars per share) | $ / shares | 0.01 | |||
Threshold Closing Price for Specified Number of Trading Days (in dollars per share) | $ / shares | $ 21 | |||
Threshold Trading Days for Sale of Shares (Day) | 20 days | |||
Threshold Consecutive Trading Days for Sale of Shares (Day) | 30 days | |||
Warrants and Rights Outstanding | $ | $ 1,279,182 | |||
Gain (Loss) on Derivative Instruments, Net, Pretax, Total | $ | $ 89,010 | |||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 126,268 | |||
Private Warrants [Member] | ||||
Class of Warrant or Right, Outstanding (in shares) | 556,313 | |||
Warrants and Rights Outstanding | $ | $ 283,720 | |||
Private Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | ||||
Derivative Liability, Measurement Input | 2.42 | |||
Private Warrants [Member] | Measurement Input, Price Volatility [Member] | ||||
Derivative Liability, Measurement Input | 74.6 | |||
Private Warrants [Member] | Measurement Input, Expected Term [Member] | ||||
Derivative Liability, Measurement Input | 3.71 | |||
Private Warrants [Member] | Measurement Input, Exercise Price [Member] | ||||
Derivative Liability, Measurement Input | 11.50 | |||
Private Warrants [Member] | Measurement Input, Share Price [Member] | ||||
Derivative Liability, Measurement Input | 2.46 | |||
Pre-Funded Warrant [Member] | ||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | |||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.0001 | |||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 5,066,600 | |||
Proceeds from Issuance of Warrants | $ | $ 19,000,000 | |||
Investor Warrant [Member] | ||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 0.75 | |||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 4.125 | |||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 6,900,000 | |||
Class of Warrant or Right, Exercised During Period (in shares) | 0 |
Note 7 - Stock Option Plan an_3
Note 7 - Stock Option Plan and Stock-based Compensation (Details Textual) - USD ($) shares in Thousands | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Share-Based Payment Arrangement, Expense | $ 39,686 | $ 0 |
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 241,712 | $ 0 |
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 2 years | 0 years |
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 0 |
Note 7 - Stock Option Plan an_4
Note 7 - Stock Option Plan and Stock-based Compensation - Stock Option Activity (Details) - $ / shares | Mar. 31, 2022 | Dec. 31, 2021 |
Options outstanding (in shares) | 192,898 | 192,898 |
Beginning balance, weighted average exercise price per share (in dollars per share) | $ 8.46 | $ 8.46 |
Vested and expected to vest (in shares) | 192,898 | |
Vested and expected to vest, weighted average exercise price per share (in dollars per share) | $ 8.46 | |
Share-Based Payment Arrangement, Option [Member] | ||
Beginning balance, number of shares available for grant (in shares) | 1,257,334 | 1,257,334 |
Note 7 - Stock Option Plans and
Note 7 - Stock Option Plans and Stock-based Compensation - Shares Outstanding Under Option Plan (Details) - $ / shares | 3 Months Ended | |
Mar. 31, 2022 | Dec. 31, 2021 | |
Options outstanding (in shares) | 192,898 | 192,898 |
Weighted average remaining contractual life (Year) | 6 years 6 months 3 days | |
Shares exercisable (in shares) | 102,053 | |
Weighted average exercise price (in dollars per share) | $ 8.46 | |
Range 1 [Member] | ||
Options outstanding (in shares) | 48,724 | |
Weighted average remaining contractual life (Year) | 7 months 6 days | |
Shares exercisable (in shares) | 48,724 | |
Weighted average exercise price (in dollars per share) | $ 11.89 | |
Range 2 [Member] | ||
Options outstanding (in shares) | 16,747 | |
Weighted average remaining contractual life (Year) | 2 years 8 months 4 days | |
Shares exercisable (in shares) | 16,747 | |
Weighted average exercise price (in dollars per share) | $ 31.33 | |
Range 3 [Member] | ||
Options outstanding (in shares) | 81,227 | |
Weighted average remaining contractual life (Year) | 9 years 25 days | |
Shares exercisable (in shares) | 20,957 | |
Weighted average exercise price (in dollars per share) | $ 4.38 | |
Range 4 [Member] | ||
Options outstanding (in shares) | 46,200 | |
Weighted average remaining contractual life (Year) | 9 years 7 months 24 days | |
Shares exercisable (in shares) | 15,625 | |
Weighted average exercise price (in dollars per share) | $ 3.72 |
Note 8 - Commitments and Cont_2
Note 8 - Commitments and Contingencies (Details Textual) | 3 Months Ended |
Mar. 31, 2022USD ($) | |
Corporate Office Lease [Member] | |
Lessee, Operating Lease, Term of Contract (Month) | 12 months |
Lessee, Operating Lease, Monthly Lease Payment | $ 1,300 |
Lessee, Operating Lease, Renewal Term (Month) | 12 months |
Minimum [Member] | |
General Product Liability Insurance | $ 5,000,000 |